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Abstract
The epithelial to mesenchymal transition (EMT) is a biological process in which a non-motile epithelial cell changes
to a mesenchymal phenotype with invasive capacities. This phenomenon has been well documented in multiple
biological processes including embryogenesis, fibrosis, tumor progression and metastasis. The hallmark of EMT is
the loss of epithelial surface markers, most notably E-cadherin, and the acquisition of mesenchymal markers
including vimentin and N-cadherin. The downregulation of E-cadherin during EMT can be mediated by its
transcriptional repression through the binding of EMT transcription factors (EMT-TFs) such as SNAIL, SLUG and
TWIST to E-boxes present in the E-cadherin promoter. Additionally, EMT-TFs can also cooperate with several
enzymes to repress the expression of E-cadherin and regulate EMT at the epigenetic and post- translational
level. In this review, we will focus on epigenetic and post- translational modifications that are important in
EMT. In addition, we will provide an overview of the various therapeutic approaches currently being
investigated to undermine EMT and hence, the metastatic progression of cancer as well.
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Background
Epithelial-mesenchymal transition (EMT) is a biological
process in which non-motile, polarized epithelial cells
undergo a series of biochemical alterations, becoming
motile non-polarized mesenchymal cells with invasive
capacity, resistance to apoptosis and altered biosynthesis
of extracellular matrix (ECM) components. Epithelial and
mesenchymal cells differ in their morphology and tissue
organization. In a typical epithelium, cells are organized
either as a single layer or in multi-layered sheets. In the
latter case, structure is maintained through cell-cell inter-
actions including tight junctions, gap junctions, cadherin
based adherent junctions, desmosomes and ECM inter-
actions [1, 2]. These junctions and interactions impede
the movement of individual cells within the epithelial
monolayer [3, 4]. Mesenchymal cells rarely establish
tight junctions with surrounding cells and are embed-
ded inside the extracellular matrix [5].
Cytoskeletal changes and cell signaling pathways are
altered as a cell undergoes EMT. Processes known to
contribute to EMT include the activation of transcrip-
tion factors (TFs) such as SNAIL, SLUG and TWIST,
altered expression of specific cell-surface proteins,
reorganization and expression of cytoskeletal proteins,
production of ECM-degrading enzymes, and changes in
the expression of specific microRNAs [6, 7]. EMT is
initiated following the dissolution of tight junctions
resulting in the loss of apical-basal cell polarity [8, 9].
Other types of cell junctions are disassembled as well,
such as gap and adherent junctions, leading to the loss of
basement membrane integrity. The cytoskeleton also
undergoes characteristic reorganization such as increased
allocation of actin into stress fiber formation and the
replacement of cytokeratin intermediate filaments by
vimentin. These alterations enable the transition into a
spindle-shaped cell morphology from a cuboidal/col-
umnar precursor, correspond with an increased ability
to invade surround tissue [10–12]. A cell is considered
to have undergone EMT following the loss of epithelial
marker expression in tandem with the development of
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mesenchymal marker expression. Key epithelial markers
lost include E-cadherin (CHD1), Mucin-1, Cytokeratins
(such as CK19, CK18, CK8), Occludin and Desmoplakin.
Oppositely, markers gained during the process include
N-cadherin, Vimentin, Smooth Muscle Actin (αSMA),
Fibronectin, and Vitronectin, which together comprise
the key mesenchymal markers [6, 13–16]. In addition
numerous proteins not located on the cell surface also
undergo key changes in localization. β-catenin, a com-
ponent of the cadherin complex is one such example.
During EMT, β-catenin dissociates from the cadherin
complex and is translocated into the nucleus where it
behaves as a transcription factor, regulating the expression
of several genes in key pathways such as Wnt signaling.
Importantly, the changes observed in cells to revert back
to a epithelial-like phenotype upon arrival at a suitable
location to colonize, a process prudently entitled mesen-
chymal to epithelial transition (MET) [5].
EMT has been classified into three categories: type I,
type II and type III [17, 18]. Type I occurs during em-
bryogenesis where cells need to migrate to adjacent tis-
sues in order to form new organs and tissues [5]. Type
II is associated with the wound healing, whereby fibro-
blasts repair or rebuild tissues [6]. Unlike types I and II
which perform necessary physiologic functions, type III
is a pathophysiologic adaptation of the process, and is
closely associated with progression of neoplasia occur-
ring in cells containing certain epigenetic and genetic
changes [4, 19]. It is currently theorized that exploitation
of the normal EMT signaling pathways provides the mo-
lecular genetic basis for how neoplastic (but differenti-
ated) cells can shed their epithelial characteristics and
acquire migratory properties. Having undergone such a
change, the cells are subsequently able to invade tissues
surrounding the primary tumor, extravasate into lym-
phatics or blood vessels, travel to distant sites through
the circulation, and ultimately colonize a metastatic
niche [18, 20]. It is important to highlight that onco-
genic EMT is a transient process that may function in a
paracrine fashion and is followed by MET once the
tumor cells reach the metastatic site [21].
The EMT program is activated by multiple signaling path-
ways as well as several epigenetic and post-translational
modifications such as methylation, acetylation, phos-
phorylation, glycosylation, hydroxylation and SUMOy-
lation. Epigenetic modifications including modification
of histone protein tails, and DNA promoter regions,
play a key role in regulating gene expression by defin-
ing whether chromatin at a given genomic locus will be
transcriptionally active or inactive [22]. Post transla-
tional modifications are covalent modifications that
occur after transcript has been translated into protein
[23]. Improving our understanding of how these modi-
fications function in the regulation of EMT is of crucial
importance, and likely instance where novel therapeu-
tics might be developed to better treat diseases such as
cancer [24]. Since the EMT program is regulated dually
by epigenetic and post translational modifications, we
will focus closely on these two mechanisms as they per-
tain to EMT in this review. In addition, we will provide
a current overview of the various therapeutic approaches
currently being investigated to undermine EMT.
E-cadherin as a key epithelial marker
The CDH1 gene is located on chromosome 16q22.1 and
codes for the subtype of cadherin protein expressed by
epithelial cells (E-cadherin). Functionally, E-cadherin be-
haves as a tumor suppressor gene and plays diverse roles
in regulating cell polarity, differentiation, migration and
stem cell-like properties. In the context of cell polarity,
E-cadherin binds to adjacent cells creating an intercel-
lular complex that forms epithelial barriers. The extra-
cellular portion of E-cadherin binds to cadherins on an
adjacent cell creating a bridge between the cytoskele-
tons of contiguous cells. The intracellular domain of
E-cadherin interacts with β-catenin, which itself is linked
actin filaments within the cells via a linker protein called
α-catenin [25–27].
Down-regulation or inactivation of CDH1 has been
frequently observed during tumor cell progression, and
several mechanisms have been proposed [28]. These
include germline mutations [29, 30], promoter hyper-
methylation [31, 32] and upregulation of E-cadherin
transcriptional repressors [10], alternatively known as
EMT transcription factors (EMT-TFs). Transcription
factors such as SNAIL, SLUG, ZEB1, and ZEB2/SIP1
are considered direct repressors of E-cadherin as they
bind to E-boxes present on the CDH1 promoter [10,
33, 34]. Indirect repressors include bHLH proteins
(TWIST1 and TWIST2), homeobox proteins (GSC and
SIX1), the bHLH factor E2.2 and the forkhead-box pro-
tein FOXC2 [2, 10]. Additionally, while the TWIST
proteins are commonly recognized as an indirect repres-
sors of CDH1, they can also bind directly on E-boxes 2
and 3 present on the CDH1 promoter to repress its ex-
pression [35].
Epigenetic modifications during EMT
Epigenetic modifications allow for regulation of gene activ-
ity and expression without altering the DNA sequence.
Such changes include methylation of cytosine residues in
CpG dinucleotides in the DNA; and histone modifications
at N-terminal tails including acetylation, methylation, phos-
phorylation and ubiquitination [36, 37]. DNA methylation
is a well-studied epigenetic event associated with transcrip-
tional silencing resulting from disrupted binding affinity
between gene promoters and their cognate TFs. Modifica-
tion of histones on the other hand alters gene expression
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by reshaping the anatomy of the nearby chromatin result-
ing in alterations in the ability of transcriptional machinery
to access genes within the region [36]. Below, we will dis-
cuss each of these epigenetic modifications in further detail.
DNA methylation
DNA methylation is one of the fundamental epigenetic
modifications in mammals. It occurs at the 5-position
of cytosine (5mC) in CpG dinucleotides and is cata-
lyzed by DNA methyltransferases (DNMTs) [38, 39].
The DNMT family is composed of four members:
DNMT1, DNMT3A, DNMT3B, and DNMT3L. DNMT1
maintains DNA methylation during DNA replication,
while DNMT3a and DNMT3b regulate de novo DNA
methylation primarily during embryonic development.
The inactivation of CDH1 by hypermethylation is a com-
mon event in multiple human carcinomas including
breast, bladder, lung, liver, gastric and prostate [32, 40–42].
Additionally, promoter hypermethylation of the CDH1
gene is positively associated with EMT in breast cancer
cell lines, corresponding with the increased potential for
invasion and metastasis observed in these cells [43].
In murine cells, oncogenic Ras has been shown to in-
duce EMT in cooperation with certain serum factors
[44]. Dumont and colleagues [45] worked with a model
of immortalized Human Mammary Epithelial cells
(HMEC) with repressed p16INK4A (vHMEC)-express-
ing oncogenic Ras (vHMEC-ras) and showed that these
cells change morphology and became motile when cul-
tured in serum-rich media. Moreover, they reported
changes in the methylation status of several genes in-
cluding CDH1 promoter as well as ESR1 (which codes
for estrogen receptor) and TWIST in cells with a mes-
enchymal phenotype that were exposed to 10 % serum
but not in cells with the epithelial phenotype.
Several transcriptional factors including ZEB1, SNAIL
and TWIST regulate CDH1 expression (Fig. 1). ZEB1 is
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Fig. 1 Changes in the molecular markers during EMT. E-cadherin, Desmoplakin, β-catenin and α-catenin are cell-cell contact proteins that are lost
during EMT. N-cadherin, Vimentin, Fibronectin, SNAIL, Slug and Twist are mesenchymal markers that are gained during EMT
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embryogenesis and cell differentiation [46]. ZEB1 re-
presses CDH1 transcription by its binding to two E-box
sequences in the promoter. ZEB1 can also regulate
CDH1 expression at the epigenetic level. Basal-like
breast cancer (BLBC) is a breast cancer subtype
enriched with expression of mesenchymal genes and
reduced expression of epithelial genes including E-
cadherin [47]. Downregulation of CDH1 in BLBC is
mediated by ZEB1, which recruits DNMT1 to the CDH1
promoter to maintain the methylation status in the pro-
moter [38]. These results suggest that ZEB1 acts as a tran-
scriptional repressor and an epigenetic modulator to
induce EMT in breast cancer. Although the hypermethy-
lation of CDH1 has been well-associated with EMT,
McDonald and colleagues showed that the DNA methy-
lation was unchanged during EMT in a model of mouse
hepatocytes treated with TGF-β [48]. It is important to
note that the mechanisms leading to EMT could be dif-
ferent in normal compared to cancer cells. In fact,
Dumont and colleagues [45] suggested that TGF-β sig-
naling and oncogenic stress induce EMT in human
cells.
DNA methylation inhibitors such as 5-aza-2′-deoxy-
cytidine (5-aza-CdR) have been found to function as
anticancer agents in light of their ability to reactivate
tumor suppressor gene expression [49]. However, Ateeq
and colleagues [50] have hypothesized that such demethy-
lating agents might also increase the risk of tumor metas-
tasis by inadvertently activating genes involved in invasion
and metastasis. They tested the DNA methylation in a
set of genes involved in metastasis, angiogenesis and
cell cycle regulation as well as in the tumor suppressor
gene RASSF1A after treatment with 5-aza-CdR in non-
invasive human breast cancer cells MCF7 and ZR-75-1.
They found that although treatment with 5-aza-CdR in-
creased the expression level of RASSF1A, it also increased
the expression of genes involved in metastasis, such as
uPA, SNCG, and CXCR4 [50, 51]. The mechanism respon-
sible for the increase in the expression of those genes was
attributed to demethylation at their regulatory regions.
Such findings highlight the fundamental importance of
DNA methylation in contribution to the activation of pro-
metastatic genes, and consequently, EMT.
Histone modifications
Methylation
SNAIL is a zinc finger transcription factor that regu-
lates EMT during development of the mesoderm and
neural crest [52]. In breast cancer, the expression of
SNAI1 has been shown to be upregulated in recurrent
tumors and in addition, is associated with metastasis
and decreased relapse-free survival [52]. Similar to
ZEB1, SNAIL suppresses the transcription of CDH1 by
binding to E-boxes in the CDH1 promoter [53]. It can
also cooperate with histone methyltransferases (HMT)
and DNMTs to modulate the expression of CDH1
(Table 1) [37].
KDM6B in EMT: KDM6B (also known as JMJD3) is an
α-ketoglutarate dependent demethylase containing a
conserved Jumonji C (JmjC) domain. This enzyme is
responsible for the demethylation of di- and trimethyl-
lysine 27 (H3K27m2/3) on histone H3 (Table 1).
H3K27m2/3 is an epigenetic modification associated
with gene silencing [54, 55]. It has been reported that
KDM6B expression is higher in metastatic prostate cancer
[56]. It is also highly expressed in invasive breast carcin-
omas compared to normal tissues. Moreover, during
TGFβ-induced EMT, TGF-β activates KDM6B which then
demethylates H3K27m3 at SNAI1 promoter. This epigen-
etic modification activates the transcription of SNAI1.
This suggests a role for KDM6B during tumor invasion
which was demonstrated in MDA-MB-231 cells [57].
MMSET in EMT: TWIST is a transcription factor that
regulates cell migration and tissue reorganization during
early embryogenesis but also plays an important role in
EMT and tumor metastasis [58, 59]. TWIST induces the
down-regulation of E-cadherin and increased expression
of mesenchymal markers such as Fibronectin, Vimentin,
αSMA, and N-cadherin [60]. The overexpression of
TWIST has been associated with poor prognosis in hu-
man cancers [58, 60, 61]. One mechanism by which
TWIST induces EMT is through its interaction with a
HMT. MMSET (also known as WHSC1 or NSD2) is a
HMT that was first identified as a candidate gene for
Wolf–Hirschhorn Syndrome (WHS). MMSET can di- or
trimethylate histone H3 at lysine 36 (H3K36) (Table 1)
[25, 62]. In solid tumors, MMSET is overexpressed and
associated with poor prognosis [63]. MMSET binds to
the TWIST promoter and increases its methylation at
H3K36m2. This change results in TWIST activation,
which contributes to prostate cancer progression.









KDM6B demethylates H3K27 at the SNAI1 promoter. MMSET can di- or trimethylate
H3K36 at the TWIST promoter. LSD1 methylates H3K4m2 on CDH1. Suv39H1 can
trimethylate H3K9 on the CDH1 promoter. SET8 methylates H4K20 on the CDH1
and CDH2 promoters. G9a is responsible for mono and dimethylation of H3K9
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LSD1 in EMT: Several histone demethylases regulate
E-cadherin expression. The histone demethylase LSD1
(also known as KDM1A and AOF2) plays an important
role in EMT [64]. It has been shown that SNAIL inter-
acts with LSD1 through its SNAG (SNAI1/GF) domain
and recruits LSD1 to CDH1 promoter. As a conse-
quence, methyl groups on lysine 4 of histone H3 will
be removed (H3K4m2) (Table 1). The demethylation
suppresses the expression of CDH1 and enhances cell
invasion. This mechanism suggests that LSD1 could be
a good target for a new therapeutic modality. Another
proposed therapeutic approach could be to construct
peptides that mimic the structure of the SNAG domain
of SNAIL to inhibit its function during EMT and can-
cer progression [64, 65].
SUV39H1 in EMT: Suv39H1 (suppressor of variegation
3–9 homolog 1) is a histone methyltransferase respon-
sible for the trimethylation of histone H3 at lysine K9
(H3K9m3) in the CDH1 promoter (Table 1). The mech-
anism responsible for this post transcriptional modifica-
tion is through the interaction of SNAIL with Suv39H1.
This interaction leads to the recruitment of Suv39H1 to
the CDH1 promoter to repress its transcription. The
suppression of Suv39H1 could be a good therapeutic ap-
proach to rescue CDH1 expression in cancers where the
DNA methylation levels are high, such as in BLBC [66].
SET8 in EMT: SET8 (also known as PR-Set7/9, SETD8
or KMT5A) is a HMT of the SET domain-containing
methyltransferase family. SET8 methylates lysine 20 of
histone H4 (H4K20), and regulates transcription both
positively as well as negatively (Table 1) [67]. SET8 me-
diates the transcriptional activation of WNT target
genes [59, 68] and regulates the S-phase progression of
the cell cycle [69]. In EMT, SET8 has dual functions;
activation of N-cadherin and repression of CDH1 expres-
sion. The physical interaction between SET8 and TWIST
promotes the recruitment of SET8 to the N-cadherin pro-
moter and induces H4K20 methylation (H4K20m1). This
modification results in activation of N-cadherin expres-
sion. In contrast, H4K20m1 methylation of the CDH1
promoter represses CDH1 expression suggesting that
methylation has two distinct functions.
G9A in EMT: G9a is a HMT responsible for mono and
dimethylation of histone H3 at lysine K9 (H3K9m1
and H3K9m2) (Table 1). Methylation at this residue is
associated with repression of transcription [37]. It has
been shown that the c-terminal domain of SNAIL in-
teracts with ankyrin repeat and SET domains of G9a,
and recruits G9a and DNMTs (DNMT1, DNMT3a and
DNMT3b) to the CDH1 promoter resulting in its methy-
lation. The knockout of G9a restored CDH1 expression
and results in the inhibition of cell migration and invasion
in a model of breast cancer [70]. Although DNMT1 can
modulate the expression of CDH1 through increasing pro-
moter methylation levels, it could govern expression of
CDH1 in a methylation-independent manner as well.
DNMT1 can interact with SNAIL to prevent its inter-
action with the CDH1 promoter leading to full expression
of CDH1 [71].
When considered together, the examples discussed
above provide the current framework for the epigenetic
regulation of EMT-TFs. This type of regulation is re-
sponsible for the key TFs which lead to the suppression
of E-cadherin- a fundamental step in the initiation of
EMT program and thus is of paramount importance to
cells undergoing EMT. Designing drugs to target the
components of this process is a budding field of cancer
pharmacotherapy, but is complicated by the variable
effects which histone methylation can have on gene ex-
pression (e.g., methylation at H3K36m2 activates TWIST
gene expression, while methylation at H3K27 inactivates
SNAIL gene expression). Thus, future treatments will need
to get target specific methyltransferase or demethyltrans-
ferases in order to be effective, rather than simply altering
histone methylation in a unilateral fashion.
In the context of EMT, hypermethylation of E-cadherin
is an epigenetic modification associated with the invasive
capacity of cancer cells and occurs through the interac-
tions of EMT-TF with several HMTs and DNMTs. The
interactions among these complexes can either repress
the expression of CDH1, inducing a mesenchymal state,
or repress the expression of the EMT-TF, thereby main-
taining an epithelial state. Currently, several DNA
methylation inhibitors are approved by the US Food
and Drug Administration (FDA). One such inhibitor, 5-
Azacytidine, is well known to have good efficacy in
treating myelodysplastic syndromes [72, 73]. The iden-
tification of these epigenetic markers within a tumor
would be helpful to develop new therapeutic approaches
by targeting enzymes that modulate EMT in cancers.
Acetylation
Histone acetylation and deacetylation play important
roles in the regulation of transcription [74]. Histone
acetylation is catalyzed by Histone Acetyl Transferases
(HATs), an event which is usually associated with tran-
scriptionally active chromatin. As a result of acetylation,
positively charged lysines are neutralized which increases
accessibility to DNA. On the other hand, histone deace-
tylases (HDACs) catalyze the removal of the acetyl resi-
dues in the chromatin of inactive regions [31, 74, 75].
HATs and HDACs are usually part of multi-protein
complexes composed of co-activators or co-repressors
that are recruited to specific DNA sequences to deter-
mine the acetylation status [31]. Multiple HDACs have
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been identified in mammals and are grouped according
to their homology to deacetylases in yeast. HDAC1 and
HDAC2 are class I enzymes and have been found to be
overexpressed in some cancers [76]. HDAC1 is highly
expressed in hepatocellular carcinoma, breast, and liver,
prostate, gastric and colon cancer; and HDAC2 is overex-
pressed in colorectal, cervical and gastric cancer [77, 78].
Histone deacetylation is at least one mechanism by
which the aforementioned SNAIL represses E-cadherin
expression. SNAIL directly interacts with E-cadherin
promoter and recruits HDAC1, HDAC2 and the co-
repressor Sin3A to the CDH1 promoter to silence its
expression by deacetylation of histones H3 and H4.
This effect was abolished by treatment with the HDAC
inhibitor Trichostatin A (TSA) [31]. HDAC1 is also
required for TGFβ1-induced EMT in hepatocytes and
frequently overexpressed in hepatocellular carcinoma
(HCC), suggesting a strong connection between HDAC1
and the invasive properties of HCC. HDAC1 has been
shown to repress the epithelial genes such as CDH1
and ZO-1 [79]. In pancreatic cancer, downregulation
of E-cadherin occurs through ZEB1, which recruits
HDAC1 and HDAC2 to the CDH1 promoter to silence
its expression [80]. In contrast, in ZEB1 knockdown
cells, HDACs cannot be recruited, and as a conse-
quence, E-cadherin expression is induced in such
cases, implicating a significant role of HDAC in EMT.
Also, E-cadherin expression is regulated by SMAR1
(Scaffold/Matrix attachment region-binding protein)
which forms a complex with HDAC1 and binds to the
SLUG promoter. This results in the repression of the
transcription of SLUG, and thus restores E-cadherin ex-
pression [81]. As described above, TWIST is considered
an indirect repressor of E-cadherin. The Mi2/nucleo-
some remodeling and deacetylase (Mi2/NuRD) complex
contains multiple proteins that have activities similar to
histone deacetylase and chromatin-remodeling ATPase.
TWIST can interact with proteins in the Mi 2/NuRD/
MTA2 complex and recruit this complex to the CDH1
promoter that results in the repression of E-cadherin ex-
pression [82].
Another family of proteins that regulate acetylation is
the sirtuins. Sirtuins are class III histone deacetylases
that use nicotinamide adenine dinucleotide (NAD+) to
mediate the deacetylation of histone and non-histone
substrates. Thus, sirtuin activity is regulated by the inter-
cellular [NAD+]/[NADH] ratio [74, 83]. The sirtuin fam-
ily of proteins is composed of seven members (SIRT1-7).
SIRT1, 2, 3 and 5 target proteins in the nucleus, cyto-
plasm and mitochondria for acetylation, while SIRT 4
and 6 regulate ADP ribosylation [84]. SIRT1 deacetylates
histone H4 lysine 16 (H4K16) as well as histone H3
lysine 9 (H3K9) and histone H3 at lysine 14 (H3K14).
Some reports indicate that SIRT1 may provide genetic
stability and suppress tumor formation [85]. In contrast,
other studies indicate that SIRT1 levels are high in can-
cer samples and this is associated with poor prognosis
and metastasis [86–88]. Thus the exact role of SIRT1 in
cancer is very controversial. An example of how SIRT1
acts as a negative regulator of EMT is in oral squamous
cell carcinoma (OSCC). The expression of SIRT1 in
OSCC decreases TGF-β-mediated cell migration and
metastasis. This occurs due to high levels of SIRT1 ex-
pression and leads to the deacetylation of SMAD4, a
downstream target of TGF-β which suppresses the ex-
pression of MMP7. Downregulation of SIRT1 leads to
SMAD4 hyperacetylation and MMP7 hyperactivation
that results in the degradation of E-cadherin, the release
of β-catenin from cell junctions and translocation to the
nucleus to promote metastasis in OSCC cells [89]. On
the other hand, in prostate cancer, SIRT1 induces EMT
[90]. The mechanism is through ZEB1, which recruits
SIRT1 to the CDH1 promoter to deacetylate histone H3.
As a consequence, the RNA polymerase binding and
CDH1 transcription are reduced. These results suggest
that SIRT1 may be a good therapeutic target for prostate
cancer among others [91].
Interplay between HDAC and HMT to regulate EMT
Hypoxia is a microenvironmental condition known to
promote tumor progression through the stabilization of
Hypoxia Inducible Factor-1 (HIF-1). HIF-1α activates
genes involved in cellular processes such as angiogen-
esis, invasion and EMT [24, 58]. Under hypoxic condi-
tion, different chromatin modifiers regulate EMT [92].
WDR5 is a WD40 repeat protein and a HMT that is essen-
tial for histone H3 lysine 4 (H3K4) methylation [92, 93].
HIF-1α activates the expression of HDAC3 that deace-
tylates H3K4 on both mesenchymal genes (Vimentin
and N-cadherin) and epithelial genes (E-cadherin and
Plakoglobin). To modulate EMT, HDAC3 additionally
recruits the WDR5/HMT complex to mesenchymal pro-
moters and increases the methylation levels of H3K4m2
to promote gene activation and EMT. The knockdown of
WDR5 abolishes the activation of mesenchymal genes
during hypoxia [92]. These results suggest that hypoxia-
induced EMT is regulated by interplay between histone
deacetylases (HDAC3) and histone methyltransferases
complexes.
HDACs mediate epigenetic mechanisms with import-
ant roles in cell cycle regulation, cell proliferation and
differentiation [94]. The activity of HDACs has also
been associated with the development and progression
of fibrotic disorders [95], as well as cancer, and thus it
is important to explore potential applications of HDAC
inhibitors to inhibit EMT. However, the role of certain
HDACs is still controversial, which hinders the devel-
opment of a viable therapeutic option [81]. However,
Serrano-Gomez et al. Molecular Cancer  (2016) 15:18 Page 6 of 14
therapeutic use of HDAC inhibitors such as SAHA
(suberoylanilide hydroxamid acid), valproic acid (VPA)
and trichostatin A (TSA) has been tested in several
models of cancer showing promising results [96]. For
example, in triple negative breast cancer, Panobinostat
an inhibitor of HDAC class I, II and IV, inhibits prolifera-
tion as well as increases the expression of E-cadherin [97].
In summary, complete understanding of histone acetyl-
ation in EMT will lead to more effective cancer treatments.
Post-translational modifications during EMT
Post- translational modifications (PTMs) are covalent
modifications that occur after RNA is translated into
protein [23]. These covalent modifications include the
addition of a modifying chemical group or the addition
of another small protein to one or more residues of the
target protein [98]. PTM can either occur on a single
residue within the protein or on multiple residues
undergoing the same or different modification [99]. In
this review we will focus on hydroxylation, phosphoryl-
ation, SUMOylation and glycosylation (Table 2).
Hydroxylation
Hydroxylation is a post-translational modification that oc-
curs in proline residues [100]. The HIF-prolyl hydroxylases
(HPHs) also known as prolyl hydroxylase domain (PHD)
proteins are enzymes that use oxygen and 2-oxoglutarate
(2-OG) as co-substrates, and iron and ascorbate as cofac-
tors. PHDs sense the cytosolic concentration of oxygen and
as a result they regulate HIF-1α. PDHs hydroxylate HIF-1α
at two proline residues (Pro402 and Pro564) located in the
oxygen-dependent degradation domain (ODDD) [100].
HIF-1α activates genes involved in cellular processes
such as angiogenesis, invasion and EMT [24]. Under
normoxia, HIF-1α is hydroxylated by a family of oxygen
dependent prolyl hydroxylases (PHD1–3). The HIF-1α-
associated prolyl hydroxylase PHD2 is an important
cellular oxygen sensor that regulates HIF-1α degrad-
ation under normoxia [101]. The hydroxylated HIF-1α
is recognized by a protein complex consists of the
tumor suppressor Von Hippel-Landau protein, Elongin
B, Elongin C, and Cullin 2 and possesses E3 ubiquitin lig-
ase activity, which targets HIF-1α for polyubiquitination
and degradation. In contrast, under hypoxic conditions,
prolyl hydroxylation is inhibited leading to HIF-1α
stabilization [101]. There are elements in the tumor
microenvironment such as TGFβ that influence the ac-
tivity of HIF-1α under normoxia. TGFβ decreases
PHD2 mRNA and protein levels. As a consequence, hy-
droxylation of the ODDD domain of HIF-1α goes
down, which results in an increase of HIF-1 stability
[101] (Fig. 2). TGFβ decreases PHD2 expression in a
SMAD2/3 dependent manner. As a result of PHD2 de-
creased expression, HIF-1α is stabilized and promotes
EMT by decreasing epithelial markers such as E-cadherin
and gaining mesenchymal markers such as α-SMA and
Fibroblast Specific Protein 1 (FSP-1). TWIST is a down-
stream target of HIF-1 α and has a hypoxia-response
element (HRE) at the promoter region. Once HIF-1 α is
stabilized, it binds to the HRE of TWIST and promotes
EMT. This suggests that one of the mechanisms by which
hypoxia induces EMT is through the direct activation of
TWIST (Fig. 2).
Phosphorylation
Protein phosphorylation is the most common post
translational modification and is essential for the regu-
lation of multiple molecular pathways involved in pro-
cesses such as metabolism, transcription, differentiation
and apoptosis. Phosphorylation is catalyzed by enzymes
called Protein Kinases (PK) that catalyze the transfer of
γ-phosphate of ATP to serine, threonine or tyrosine
residues on target proteins. Protein Phosphatases (PP)
catalyze the reverse process [102–104].
Phosphorylation is another post- translational modifi-
cation known to control SNAIL [105]. GSK-3β, a well-
known kinase involved in many signaling pathways,
phosphorylates SNAIL at two consecutive motifs that
control its ubiquitination and subcellular localization.
Firstly, GSK-3β binds to SNAIL and phosphorylates
SNAIL at motif 2, which induces the nuclear export of
SNAIL. Later, the phosphorylation at motif 1 promotes
the ubiquitin-mediated proteasome degradation of SNAIL
by β-Trcp. The inhibition of GSK-3β results in the upreg-
ulation of SNAIL and downregulation of E-cadherin that
results in the activation of the EMT program [106].
SNAIL activity can also be regulated by phosphorylation
on Ser11. This residue is located within the SNAG
Table 2 Post - Translational Events in EMT.








Hydroxylated HIF-1α is stabilized and promotes EMT by decreasing epithelial
markers such as E-cadherin and gaining mesenchymal markers such as α-SMA
and FSP1. Phosphorylation of SNAIL mediated either by PKD1 or GSK-3β results
in SNAIL degradation by the proteasome. Phosphorylated Par6 interacts with
the E3-ubiquitin ligase Smurf-1 that targets RhoA for degradation, leading to
the disassembly of tight junctions. FoxM1 SUMOylation leads to repression
of miR-200 tumor suppressors that enhance the expression of E-cadherin
and suppress the expression of ZEB1 and ZEB2. TFAP2C undergoes SUMOylation
that blocks its ability to induce the expression of luminal genes and helps it
to maintain basal like features. SIP1 SUMOylation leads to the recruitment of
the co-repressor CtBP which maintains CDH1 expression. Lastly, SNAIL is
glycosylated under hyperglycemic conditions to promote EMT
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domain that corresponds to the SNAIL transcriptional
repression domain. In prostate cancer, the protein kin-
ase D1 (PKD1) acts as a regulator of EMT. PKD1 medi-
ates the phosphorylation at Ser11 of SNAIL. Once
phosphorylated, 14-3-3σ binds to SNAIL and SNAIL
can no longer function on E-cadherin [107]. These re-
sults suggest that PKD1 acts as a tumor and metastasis
suppressor as it regulates Snail-mediated EMT. Fur-
thermore, phosphorylation at Ser 11 of SNAIL medi-
ated by PKD1 serves as a binding site for FBXO11, an
E3 ligase that promotes SNAIL ubiquitination and deg-
radation [108]. These results establish a mechanism of
post translational regulation of EMT mediated by the
PKD1-FBXO11-SNAIL axis (Fig. 3a).
Several tyrosine kinase receptors can also activate EMT.
Epidermal Growth Factor Receptor (EGFR) is a transmem-
brane glycoprotein with an intracellular protein tyrosine
kinase domain. The activation of EGFR by EGF, results in
the activation of multiple pathways including ERK-1/2,
PI3K and Stat3 via phosphorylation [109]. The overexpres-
sion of EGFR is associated with tumor progression and
poor prognosis [110]. Lu and colleagues showed that the
treatment of cancer cells that overexpress EGFR with EGF
increased cell motility and invasion by the rapid dephos-
phorylation of focal adhesion kinase (FAK). Tumor cells
with inactive FAK are less adherent to the extracellular
matrix (ECM), which promotes cell motility, invasion, and
metastasis [110]. The disassembly of tight junctions during
EMT can occur in a SMAD independent manner as well.
TGFβRI and Par6 coexist in the tight junctions. Upon
stimulation of TGFβ, the TβRI- TβRII hetero-dimerize,
resulting in a complex containing TβRII/TβRI and Par6 in
each tight junction. This interaction results in phosphoryl-
ation of Par6 at Ser345, which is mediated by TβRII [111].
Phosphorylated Par6 interacts with the E3-ubiquitin ligase
Smurf-1 that targets RhoA for degradation, leading to the
disassembly of tight junctions (Fig. 3b). Thus TGF- beta
signaling has good therapeutic value [112, 113].
Although aberrant phosphorylation of multiple pro-
teins in different pathways is a major event during
cancer development and progression, the design of vi-
able therapeutic targets that inhibit this event seems
Fig. 2 Hydroxylation of HIF1A. In the presence of oxygen, HIF-1α is hydroxylated by PHD2. This hydroxylation is recognized by a protein complex
containing Cullin 2, VHL, Elongin B, and Elongin C that targets HIF-1α for ubiquitination and leads to proteasome degradation of HIF1α. During
EMT, the activation of TGF β decreases transcription of PHD2, which leads to the stabilization of HIF-1α. The stabilized HIF-1α binds to the
hypoxia-response element (HRE) of the TWIST promoter along with HIF-1β to induce its transcription. (Blue arrowhead indicates sequential
patterns. indicates inhibition. Purple arrowhead indicates translocation.)
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challenging and the consequences may not be benefi-
cial in all carcinomas. For example, phosphorylation of
SNAIL mediated either by PKD1 or GSK-3β results in
SNAIL degradation by the proteasome. This suggests
that a good therapeutic target would be to induce the
expression of GSK-3β to promote SNAIL degradation
by the proteasome, which would in turn inhibit EMT.
However, the inhibition of GSK-3β is also a viable
therapeutic target [114]. As mentioned above, the de-
sign of therapeutic targets in cancer should be done
with caution because many proteins can have dual
functions as “suppressors” or “oncogenes” as in the
case of GSK-3β and TGFβ whose biological effects
may be different.
SUMOylation
SUMOylation is another post-translational modification
characterized by the reversible binding of Small
Ubiquitin-like MOdifier (SUMO) to the target protein.
The three-dimensional structure of SUMO is similar to
ubiquitin [115, 116]. The SUMOylation of a target pro-
tein is mediated by a cascade of reactions involving an
activating enzyme (e.g., SAE1/2), E2-conjugating enzyme
(e.g., UBC9), and an E3 ligase. SUMO groups can be
deconjugated by a group of Sentrin/SUMO-specific pro-
teases (SENP) [116].
Forkhead box protein M1(FoxM1) is a transcription
factor that belongs to a large family of forkhead box
(Fox) transcription factors, which are characterized by
the presence of a DNA-binding domain called the fork-
head box or winged helix domain [117]. FoxM1 is
expressed in proliferating cells and plays an important
role in cell cycle progression stimulating the expression
of genes involved in G1–S and G2–M progression [118].
It has been shown that FoxM1 is highly expressed in
breast cancer [119]. FoxM1 can promote EMT through
its direct binding at the SLUG promoter [120]. FoxM1 is
subject to SUMOylation at lysine 463 and this posttrans-
lational modification is required for the full repression
of miR-200b/c in breast cancer cells [121]. Members of
the miR-200 family act as tumor suppressive miRNAs,
enhancing the expression of E-cadherin and suppressing
the expression of ZEB1 and ZEB2. Thus, the overexpres-
sion of miR-200 results in a reduced expression of ZEB
transcription factors and enhanced expression of epithe-
lial makers [121–123]. In pancreatic cancer, FoxM1 is
overexpressed and promotes EMT by the up-regulation
of mesenchymal cell markers such as ZEB1, ZEB2,
SLUG, and vimentin [117] (Fig. 4a).
The transcription factor activator protein 2C (TFAP2C)
is very important in breast cancer biology, especially in lu-
minal subtypes as it regulates genes including estrogen
Fig. 3 Phosphorylation of SNAIL and Par6. (Blue arrowhead indicates sequential patterns. indicates inhibition. Purple arrowhead indicates
translocation.) a. SNAIL phosphorylation that suppresses EMT. GSK-3β phosphorylates SNAIL at two consecutive motifs. First, the phosphorylation
at the second motif induces the cytoplasmic translocation of SNAIL from the nucleus. In the cytoplasm, SNAIL is phosphorylated on motif 1, and
this phosphorylation is recognized by β-Trcp which targets it for proteosomal degradation of SNAIL. PKD1 is another kinase that phosphorylates
SNAIL so it can be recognized by β-Trcp and FOXO11 that target it for proteosomal degradation. b. Mechanisms of EMT activation mediated by
TGFβR. The activation of TGFβR results in the phosphorylation of Par6, and in turn activation of SMURF1 that targets RHOA degradation by the
proteasome, which contributes to the disassembly of the tight junctions
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receptor-alpha (ERα) and HER2/c-erbB2. The expression of
TFAP2C is critical for maintaining the luminal phenotype
of breast cancer cells. The loss of TFAP2C in luminal breast
cancer cell lines induces luminal to basal transition accom-
panied by an increase in the expression of mesenchymal
markers (Vimentin and N-cadherin) and loss of E-cadherin.
These results suggest that TFAP2C plays an important role
in the regulation of luminal-specific genes [124]. TFAP2C
undergoes SUMOylation that blocks its ability to induce
the expression of luminal genes and helps it to maintain
basal like features. The disruption of SUMOylation of
TFAP2A induces a basal-to-luminal transition [125]. Al-
though this mechanism is not directly related to EMT, it
shows evidence of a transition to a more aggressive intrinsic
subtype of breast cancer which as mentioned before, is
characterized by high expression of mesenchymal genes.
Smad-Interacting Protein 1 (SIP1) is a member of the
zfh-1 family and plays important functions during em-
bryonic development. SIP1 has a binding motif for the
corepressor C-terminal-binding protein (CtBP). SIP1 can
induce EMT through the recruitment of CtBP to the
CDH1 promoter to repress its transcription. SIP1 is a
target for SUMOylation mediated by the polycomb pro-
tein Pc2. This post- translational modification attenuates
transcription of SIP1 and disrupts the recruitment of the
corepressor CtBP. As a consequence, CDH1 expression
is maintained [126] (Fig. 4b). One of the mechanisms by
which TGFβ regulates EMT is by the downregulation of
the PIAS1 (protein inhibitor of activated STAT) which is
a SUMO E3 ligase [127, 128]. It has been shown that the
activation of PIAS1 suppresses the ability of TGFβ to ac-
tivate matrix metalloproteinase 2 (MMP2) and invasive
properties of breast cancer cells. In vivo, the disruption
of the activity of PIAS1 in MDA-MB-231, enhance the
development of bone metastasis after intracardiac injec-
tions of the cancer cells [127]. These results suggest that
PIAS1 suppresses breast cancer metastasis through the
inhibition of TGFβ.
SUMOylation plays an important role in the regulation
of gene expression, genome instability, cellular functions,
cellular senescence and stem cell reprogramming [129].
Furthermore, several investigators linked SUMO modifi-
cation to other important diseases such as neurodegen-
erative disorders and heart diseases [130–133]. The
addition of SUMO groups to transcription factors usu-
ally results in a decrease of gene expression of the target
gene, which in turn results in the repression of E-
cadherin and activation of mesenchymal genes.
Glycosylation
The O-linked β-N-acetylglucosamine (O-GlcNAc) modifi-
cation is a monosaccharide addition that occurs in nuclear
and cytoplasmic proteins such as transcription factors,
cytoskeletal proteins, nuclear pore proteins, oncogenes,
and tumor suppressors specifically on serine (Ser) or
threonine (Thr) residues. The uridine 5′-diphospho-N-
acetylglucosamine (UDP-GlcNAc) is transferred to serine
or threonine residues by the O-GlcNAc transferase
(OGT) to produce the O-GlcNAc modification, while the
removal of the modification is performed by an O-
GlcNAcase [134, 135].
In signal transduction cascades, the O-GlcNAcylation
interplays with O-phosphorylation to regulate the func-
tion of several proteins [134, 136]. The inhibition of
GSK3β results in the increase of O-GlcNAcylation of
proteins including heat shock proteins, tubulin beta and
vimentin; and at the same time decreases this modifica-
tion on other proteins such as members of the hnRNP
superfamily [136]. SNAIL is subject to O-GlcNAc at
Ser 112 under hyperglycemic conditions. This modifica-
tion leads to stabilization of SNAIL by inhibition of its
O-phosphorylation, which is mediated by GSK3β. Con-
sequently, the O-GlcNAc SNAIL promotes EMT [134]
(Fig. 5). As discussed, EMT occurs due to the downreg-
ulation of epithelial markers and upregulation of mes-
enchymal markers such as vimentin, N-cadherin and
fibronectin [137]. Oncofetal fibronectin (onfFN) is
expressed in cancer or fetal cells/tissues, but not in
normal adult cells/tissues and can be identified using
mouse mAb FDC6. This antibody reacts with a specific
O-glycosylated peptide sequence in IIICS domain of
A B
Inhibits epithelial phenotype
Fig. 4 SUMOylation of SIP1 and FoxM1. (Blue arrowhead indicates
sequential patterns. indicates inhibition.) a. Sumoylation of FOXM1
represses the expression of miR-200b/c, which normally acts as a
tumor suppressor and reduces the expression of transcription factors
ZEB1 and ZEB2.As a consequence epithelial phenotype is inhibited.
b. Sumoylation of SIP1 decreases its transcription, which in turn prevents
recruitment of CtBP to E-cadherin promoter. As a consequence, CtBP
cannot prevent E-cadherin expression, which results in the maintenance
of the expression of epithelial genes
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onfFN. It has been shown that the treatment with TGFβ
in human prostate epithelial cell lines, induces the
addition of O-glycan at a specific threonine at the type
III homology connective segment (IIICS) domain of FN
which is associated with the change in the morphology
of the epithelial cells to fibroblast morphology, decrease
of epithelial markers and an increase in the motility of
these cells. The knockdown of this modification inhibits
the TGF-β–induced up-regulation of onfFN and EMT
process [138]. SNAIL is regulated by phosphorylation
as well as glycosylation. Phosphorylation of SNAIL
promotes its degradation. Oppositely, glycosylation of
SNAIL stabilizes the protein under conditions of
hypoglycemia. This raises one interesting question re-
garding the effect of glycosylation of SNAIL in normo-
glycemic conditions. It remains unclear what effect
glycosylation of SNAIL has in cancer.
Conclusion
Approximately 90 % of cancer mortalities occur in pa-
tients with tumors derived from epithelial tissues, and
the primary cause of death in such cases results from
dissemination of tumor cells to distant organs [139]. As
such, understanding the cellular mechanisms contribut-
ing to metastasis is paramount in the effort to improve
outcomes. EMT is a process in which tumor cells within
the primary tumor lose their cell junctions and their epi-
thelial morphology changes to fibroblastoid morphology.
These changes allow the cells to invade the surrounding
tissue of the primary tumor, intravasate into the blood-
stream and lymphatic vessels as circulating tumor cells
(CTC), and extravasate to distant sites where they may
colonize distant organs as epithelial metastasis. Although
EMT is a process that occurs under normal conditions
such as wound healing and embryogenesis, the mis-
appropriation of these pathways during tumor progres-
sion is an unpredictable and disastrous event with the
simultaneous activation of different molecular cascades.
Many pharmacological approaches, including chemical
inhibitors and monoclonal antibodies that target several
proteins that regulate cancer progression have been de-
vised and show promising results for the treatment of a
variety of cancers. However, very little research has been
done to target post translational modifications of pro-
teins in cancers, and thus we believe that identifying in-
hibitors for post-translational modifications represents
an underexplored area which may hold significant po-
tential, and thus should be a high priority in the devel-
opment of future cancer treatments. Furthermore, the
identification of these post-transcriptional and post-
translational modifications is important given that these
changes could be identified in the primary tumor before
metastasis occurs. Such knowledge would allow clini-
cians to better predict which patients have genotypes
more likely to follow an aggressive clinical course prone
to development of metastases. These patients could then
Fig. 5 SNAIL Glycosylation. SNAIL is subject to O-linked glycosylation under hyperglycemic conditions. Consequently, the O-GlcNAc SNAIL promotes
EMT by translocating it to the nucleus to bind to the E-cadherin promoter. (Purple arrowhead indicates translocation.)
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be treated with different approaches from the onset of
disease to reduce the risk of metastasis, and allow for
better prognoses and ultimately, enhance survival.
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